Shield Therapeutics receives FDA approval for Feraccru® | Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim
26 Jul 2019
SP Angel Healthcare - Morning Comment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare - Morning Comment
- Published:
26 Jul 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
4
Shield Therapeutics receives FDA approval for Feraccru® | Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim